Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Cytogen's ProstaScint

This article was originally published in The Gray Sheet

Executive Summary

Cytogen's ProstaScint: C.R. Bard will copromote the prostate cancer diagnostic capromab pendetide under a 10-year agreement announced Aug. 1. The deal calls for Bard to market the monoclonal antibody imaging agent to office and hospital-based urologists. Cytogen will be responsible for the completion of clinical trials, regulatory activities related to the PLA, manufacturing, distribution and marketing to the medical imaging community. Both companies will market the monoclonal antibody-based product to managed care organizations. Cytogen has said it plans initially to restrict availability of the imaging agent to certified sites. On July 22, FDA's Medical Imaging Drugs Advisory Committee unanimously recommended ProstaScint for detection of metastatic prostate cancer in high-risk patients to aid surgical staging and to detect recurrence of prostatic carcinoma...

You may also be interested in...

The Rebate Rule May Not Last, But It Changed The Pricing Debate

Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.

Moderna Gets To Watch And Learn From Pfizer’s COVID-19 Vaccine Advisory Committee

US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.

Sabinsa Reaches Out To US Regulators To Squeeze Fake Vitamin C Out Of Ingredient Markets

Sabinsa provided FDA and FTC with documentation of “an ingredient falsely marketed and sold as vitamin C derived from amla fruit (Emblica officinalis), which two independent labs have confirmed is actually derived from corn, sugarcane or other plants.”




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts